Opinion|Videos|January 27, 2025
Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines
Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates and highlight the underlying rationale and data supporting this approach.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5